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ORIGINAL ARTICLE
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Abstract
Synthetic glucocorticoids are potent anti-inflammatory drugs but show dose-dependent
metabolic side effects such as the development of insulin resistance and obesity. The precise
mechanisms involved in these glucocorticoid-induced side effects, and especially the
participation of adipose tissue in this are not completely understood. We used a combination
of transcriptomics, antibody arrays and bioinformatics approaches to characterize predniso-
lone-induced alterations in gene expression and adipokine secretion, which could underlie
metabolic dysfunction in 3T3-L1 adipocytes. Several pathways, including cytokine signalling,
Akt signalling, and Wnt signalling were found to be regulated at multiple levels, showing that
these processes are targeted by prednisolone. These results suggest that mechanisms by which
prednisolone induce insulin resistance include dysregulation of wnt signalling and immune
response processes. These pathways may provide interesting targets for the development of
improved glucocorticoids.
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Introduction
Synthetic glucocorticoids (GCs) such as prednisolone and
dexamethasone are widely used for the treatment of inflam-
matory diseases such as rheumatoid arthritis, asthma, inflam-
matory bowel disease and psoriasis (Del Rosso Do, 2006;
Hillier, 2007; Schwartz & Cohen, 2008). Despite their
excellent efficacy, GC usage is hampered because of adverse
(metabolic) side effects, such as insulin resistance, glucose
intolerance, diabetes, central adiposity, dyslipidemia, skeletal
muscle wasting and osteoporosis (De Bosscher & Haegeman,
2009; Rhen & Cidlowski, 2005; Rockall et al., 2003; Schacke
et al., 2002, 2006). The precise mechanisms involved in these
GC-induced side effects are not completely understood and
are tissue specific (Chrousos & Kino, 2009; Kino, 2007; Lu &
Cidlowski, 2006; van Raalte et al., 2009). One of the key
tissues thought to be involved in metabolic side effects is the
adipose tissue. Several studies have shown that the side-
effects of GCs in adipose tissue include the development of
central adiposity (Rockall et al., 2003), dyslipidaemia
(Taskinen et al., 1983; Wajchenberg, 2000) and the inhibition
of insulin-stimulated glucose uptake (Bazuine et al., 2004;
Buren et al., 2002, 2008; Sakoda et al., 2000).
It is now well established that adipose tissue is not only
involved in energy storage, but also functions as an endocrine
organ that secretes hundreds of bioactive substances known
as adipokines (Kershaw & Flier, 2004; Ouchi et al., 2011;
Lehr et al., 2011). Previously, GCs have been found to affect
the secretion of several adipokines, including TNF-a, IL-6,
Resistin, Adiponectin and Leptin in rodents (Fasshauer &
Paschke, 2003). Because recent proteomic approaches have
led to the characterization of numerous novel adipokines, we
applied a combination of genomics, antibody arrays and
bioinformatics approaches to identify prednisolone-induced
alterations in (adipokine) gene expression and secretion which
could potentially underlie prednisolone-induced metabolic
dysfunction of 3T3-L1 adipocytes.
Materials and methods
Set up of the study
In this study, differentiated 3T3-L1 adipocytes were treated
with prednisolone or DMSO for 0, 1, 6, 24 and 48 h and the
effects of prednisolone were studied at gene expression and
protein secretion level.
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Cell culture
3T3-L1 pre-adipocytes obtained from ATCC were cultured
and differentiated in adipocytes as previously described
(van den Berghe et al., 1994). Cells were used seven days
after completion of the differentiation process. Only cultures
in which495% of cells displayed adipocyte morphology were
used. Prior to use, adipocytes were serum starved for 16 h
with DMEM supplemented with 0.5% foetal bovine serum.
Analysis of insulin signalling
Differentiated 3T3-L1 adipocytes, grown in 12-well plates,
were incubated with prednisolone (1 mM) or DMSO at day
8 for 48 h. After incubation with prednisolone or DMSO, cells
were serum-starved for 2 h, and then stimulated with insulin
(100 nM) for 10 min. Following insulin stimulation, cells were
washed twice with ice-cold PBS, and lysed as described
previously (Linssen et al., 2011). Protein expression and
phosphorylation were determined by Western blotting
as described (Linssen et al., 2011) using the following
antibodies: phospho-insulin receptor substrate 1-Tyr1222,
phospho-Akt-Thr308, phospho-Akt-Ser473 (all from
Cell Signaling Technology, Danvers, MA, USA), total Akt,
phospho-Akt substrate of 160-kDa (AS160), total AS160
(all from Millipore, MA, USA), glucose transporter
4 (GLUT4), and b-actin (both from Abcam, Cambridge, UK).
Assay of 2-deoxy-D-glucose (2DOG) uptake
Differentiated 3T3-L1 adipocytes, grown in 12-wells plates,
were incubated with prednisolone (1 mM) or DMSO at day
8 for 6, 24 and 48 h. After incubation with prednisolone or
DMSO for the indicated times, the cells were washed once
with HEPES buffer, consisting of 50 mM HEPES, 0.14 M
NaCl, 1.85 mM CaCl2, 1.3 mM MgSO4, and 4.8 mM KCl [pH
7.4]), and then incubated in this buffer for an additional hour
at 37C. Then, cells were stimulated with insulin (100 nM) or
kept untreated. After 15 min, 2DOG uptake was initiated by
the addition of 2-deoxy-D-[14C] glucose (0.075 mCi per well)
in 3 mM 2DOG. After 10 min, the assay was terminated
by three quick washes with ice-cold PBS. Cells were lysed
in 0.1 M NaOH, 0.2% SDS, whereafter incorporated 2-deoxy-
D-[14C] glucose was determined by liquid scintillation
counting.
RNA isolation
Differentiated 3T3-L1 adipocytes grown in 6-well plates were
incubated with prednisolone (1 mM) for 1, 6, 24 and 48 h and
used for RNA isolation and whole-genome expression
profiling. RNA was isolated using Tripure (Roche), and
subsequently purified using the RNeasy mini kit according to
the manufacturer’s protocol (Qiagen Benelux B.V. Venlo, The
Netherlands). To remove residual traces of genomic DNA, the
RNA was treated with DNase I (Invitrogen, Leek, The
Netherlands) while bound to the RNeasy column. Quality and
quantity of the purified RNA was controlled using a
NanoDrop spectrophotometer (Nanodrop Technologies,
Montchanin, DE, USA). RNA integrity was investigated by
using the 2100 Bioanalyser (Agilent technologies,
Philadelphia, PA, USA).
Whole-genome expression analysis using Affymetrix
GeneChip Mouse Genome 430 2.0 Array
Amplification of 20 ng total RNA was performed with the
Two-Cycle Eukaryotic Target Labeling kit (Affymetrix, Santa
Clara, CA). Briefly, after the first round of cDNA synthesis,
an unlabeled ribonucleotide mix (MEGAscript T7 kit,
Ambion) was used to generate unlabelled cRNA according
to the protocol of Affymetrix. After cleanup of the cRNA with
a GeneChip Sample Cleanup Module IVT Column
(Affymetrix, Santa Clara, CA), the unlabelled cRNA con-
centration was determined and 150 ng was reverse transcribed
using random primers. Subsequently, the T7-Oligo(dT)
Promoter Primer was used in the second-strand cDNA
synthesis to generate double-stranded cDNA containing T7
promoter sequences. The resulting double-stranded cDNA
was then amplified and biotin labelled using the IVT Labeling
kit (Affymetrix, Santa Clara, CA). Biotin-labelled cRNA was
fragmented at 1 mg/ml following the manufacturer’s protocol.
After fragmentation, cRNA (10 mg) was hybridized at 45 C
for 16 h to the Human Genome U133 2.0 Plus array
(Affymetrix, Santa Clara, CA). Following hybridization, the
arrays were washed, stained with phycoerythrin-streptavidin
conjugate (Molecular Probes, Eugene, OR), and the signals
were amplified by staining the array with biotin-labelled anti-
streptavidin antibody (Vector Laboratories, Burlingame, CA)
followed by phycoerythrin-streptavidin. The arrays were laser
scanned with a GeneChip Scanner 3000 7G (Affymetrix,
Santa Clara, CA) according to the manufacturer’s instruc-
tions. Data was saved as raw image file and quantified using
AGCC v 1.0 (Affymetrix, Santa Clara, CA).
Murine adipokine antibody arrays
This array allows simultaneous detection of 308 secreted
mouse proteins in cell culture supernatants (AAM-BLM,
L-series, Raybiotech, Inc, Norcross, GA). Differentiated 3T3-
L1 adipocytes were subjected to 4 h pred/dmso, followed by
two rinsing steps and culture medium containing 0.2% FBS and
Prednisolone or vehicle (1 mM) for 44 h. To prepare samples for
the antibody array, samples were subjected to centricon tubes
(Millipore amicon ultra-15 ultracel 3 K) and washed three
times with PBS, pH 8.0. Finally proteins were recovered in 2 ml
PBS. Samples were biotin-labelled according to manufac-
turer’s protocol. Then, membranes were blocked and incubated
with the biotinylated samples overnight at 4 C, and finally
incubated with HRP conjugated streptavidin. Signals were
detected using enhanced chemiluminescence and quantified on
a LumiIMager system using LumiAnalyst software version 3.1
(Roche Diagnostics, Mannheim, Germany).
Gene expression data
Microarray data were analysed with packages from the
BioConductor library. Gene expression data was normalized
using gcrma. Identification of regulated probes was done
using limma package from Bioconductor. For identifying
differentially expressed probes after incubation with prednis-
olone, the following selection criteria were used: fold change
42, intensity 420, and p value 50.05 after correction for
multiple testing using the Benjamini-Hochberg correction.
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All statistical analysis was performed in R. Significance of
regulation of the Wnt pathway has been calculated using
globaltest.
Secreted protein data obtained from murine
adipokine antibody arrays
Regulated proteins as a result of prednisolone treatment have
been selected using a p value 50.05 (calculated using a
standard Student’s t-test).
Keyword enrichment analysis
Keyword enrichment analysis on the microarray data was
performed using CoPub, a text mining algorithm that detects
co-occurring biomedical concepts in abstracts from the
MedLine literature database (Fleuren et al., 2011), using the
following settings for the threshold values: p value 50.05,
R-scaled score435 and abstract count43. A heat map of the
pathway terms was been generated using a transformation of
the p value in the following way:
Pval transform ¼ 1ð1 þ 6  expð0:35  log 10ðp valueÞÞÞ
Additional gene annotation enrichment analysis was done
using the functional annotation module of Database for
Annotation, Visualization and Integrated Discovery (DAVID)
tool (Huang da et al., 2009a, b) with default settings against
the KEGG pathway database.
Results
Effect of prednisolone on insulin action in 3T3-L1
adipocytes
Exposure of differentiated 3T3-L1 adipocytes to 1 mM
prednisolone had no effect on the expression of key signalling
molecules, like the insulin receptor b-subunit, Akt, AS160
and GLUT4. Prednisolone significantly impaired the phos-
phorylation of Akt-Thr308 and Akt-Ser473 in response to
insulin, whereas no effects were observed on IRS1-Tyr1222
(Figure 1). Intriguingly, but in line with a study on the effects
of dexamethasone on insulin action in 3T3-L1 adipocytes
(Hoehn et al., 2008), prednisolone did not impact on insulin-
induced phosphorylation of AS160-Thr642 (Figure 1).
The mechanism(s) underlying this discordance in signalling
from Akt to AS160 is not understood. Nevertheless, prednis-
olone was found to impair insulin-stimulated glucose uptake
already after 6 h of incubation, and this inhibition was still
present at 48 h after incubation (Figure 1). These findings are
in line with earlier observations using dexamethasone in 3T3-
L1 adipocytes (Bazuine et al., 2004; Hoehn et al., 2008) and
confirm the induction of insulin resistance by prednisolone in
our experimental conditions.
Whole genome expression profiling
We next studied prednisolone-induced changes in gene
expression following exposure of 3T3-L1 adipocytes to
prednisolone or DMSO for 1, 6, 24 and 48 h. Principle
Component Analysis (PCA) showed a separation between
prednisolone- and DMSO-treated samples after 6, 24 and 48 h
(Supplementary figure 1). At each time-point, the signifi-
cantly differentially expressed probes were identified between
cells treated with prednisolone and DMSO (Supplementary
Table 2). Comparison of probes significantly affected by
prednisolone at 6 h with probes significantly affected by
prednisolone at 48 h showed that probes with a high fold
change are found to be regulated at both time points
(Figure 2). Probes which are only regulated at 6 h or at 48 h
have a lower fold change.
The same trend was observed when comparing prednisol-
one induced probes at 6 h with prednisolone induced probes at
24 h (Figure 2B). At all time points, 25 genes represented by
34 probes (in fact 26 genes were found, but for probe
1434025_at we could not find annotation), were found to be
significantly regulated by prednisolone (Table 1). Most of
these genes were up-regulated and showed a sustained
response to prednisolone at all time points, starting after 1 h
of incubation, with the highest response after 6 h, and still
present after 48 h of incubation.
Biological pathways targeted by prednisolone
To identify biological pathways that were affected by
prednisolone, we mapped the regulated genes to biological
pathway terms using the text mining algorithm CoPub
(Fleuren et al., 2011) (Figure 3). It appeared that the most
significant pathway terms could be divided into three
categories:
 immune system/inflammation (eicosanoid metabolism,
prostaglandin metabolism, cytokine receptors, cytokine
network, immune system, platelet activation),
 general metabolism (fatty acid metabolism, glucose
metabolism, gluconeogenesis, lipid metabolism, fatty
acid metabolism, glycolysis) and
 signalling (insulin signalling, TGF- signalling, Akt
signalling, Wnt signalling, MAPK signalling).
Additional functional analysis of these regulated genes
using DAVID, an annotation server based on GeneOntology
and KEGG pathways (Huang da et al., 2009b), gave similar
results (results not shown).
We are interested in mechanisms and pathways that could
underlie prednisolone-induced metabolic dysfunction and
more specific prednisolone-induced insulin resistance in
adipocytes. Therefore for the remainder of the paper, we
focused on pathways that are known to play a role in the
disturbance of insulin signalling that eventually could lead to
insulin resistance, i.e. Akt/insulin signalling, cytokine signal-
ling, TGF-b signalling and MAPK signalling. Furthermore,
we also focused on pathways that play a role in the
disturbance of adipocyte differentiation that could lead to
dyslipidaemia and obesity, i.e. Wnt signalling and cytokine
signalling. In Figure 4 the prednisolone-induced genes have
been categorized according to these pathways. Genes that
have an effect on insulin signalling, e.g. growth-factor insulin-
like growth factor I (Igf1), insulin receptor substrate 1 (Irs1)
and platelet derived growth factor receptor, beta polypeptide
(Pdgfrb) and genes from the TGF-b pathway such as MAD
homolog 3 (Drosophila) (Smad3), gremlin 1 (Grem1), trans-
forming growth factor, beta 2 (Tgfb2) and transforming
growth factor, beta induced (Tgfbi) were down-regulated.
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Figure 1. Effect of prednisolone on insulin action in 3T3-L1 adipocyte cells. Effects on protein expression of the insulin receptor (IR) b-subunit, Akt,
AS160, and GLUT4, as well as the phosphorylation of insulin receptor substrate 1 (IRS1-Tyr1222), Akt-Thr308, Akt-Ser473, and AS160-Thr642 were
determined by Western blotting in cells exposed to 1mM prednisolone for 48 h prior to stimulation with insulin (10 min, 100 nM). Data are presented as
mean standard error of the mean of 44 independent experiments (A–D), and representative Western blots (F). E. Effect of prednisolone on
2-deoxyglucose uptake in in 3T3-L1 adipocytes after 6, 24 and 48 h of incubation with prednisolone. Data are mean standard error of the mean of44
independent experiments. In all bar graphs, open columns represent the basal condition, and filled bars depict insulin-stimulated cells. The effects of
prednisolone on insulin action were analysed using a two-way ANOVA followed by Bonferonni analysis for multiple comparisons. ***Indicates a
p50.001; **p50.01. Effects of insulin versus basal were analysed using a Student’s t-test. ###p50.001; ##p50.01; #p50.05.
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Phosphatase and tensin homolog (Pten) an important regu-
lator of the Akt pathway was up-regulated.
The majority of the genes coding for cytokines, such as
Interleukin-6 (Il-6), chemokine (C-X-C motif) ligand 5
(Cxcl5), chemokine (C-X-C motif) ligand 10 (Cxcl10) and
chemokine (C-C motif) ligand 7 (Ccl7), were down regulated
by prednisolone. Other cytokines such as interleukin 1
receptor, type I (IL1r1) and interleukin 1 receptor accessory
protein (IL1rap) were up regulated.
Many Wnt signalling pathway members were significant
down regulated by prednisolone in our study. We observed
down regulation of frizzled receptors Fzd1, Fzd2, Fzd4, Fzd5
together with ligand wingless-related MMTV integration site
5A (Wnt5A) and antagonist secreted frizzled-related protein 2
(Sfrp2). Also several down-stream molecules such as Wisp1,
Wisp2, Id2 were down regulated (Figure 4).
Regulation of adipokines measured after 48 h of
incubation with prednisolone
The microarray data showed several transcripts that encode
hormones secreted by adipocytes, like cytokines, and regu-
lators of the Wnt, Akt and TGF-b pathway. We therefore
decided to study to what extend the altered levels of gene
expression would lead to changes in protein expression, by
analyzing the effects of prednisolone on adipokine secretion
by 3T3-L1 adipocytes treated with DMSO or prednisolone for
48 h. For this purpose, the supernatants of the 3T3-L1
adipocytes that were used in the gene expression study were
analysed. Out of the 308 proteins on the array, 25 proteins
were significant regulated by prednisolone (Table 2, p value
50.05. For all proteins, see Supplementary Table 1). The
majority of these proteins are cytokines involved in inflam-
matory and immune response related processes (indicated
with a purple background in Table 2). Cytokines such as
CXCL2, CCL3, CCL9, IL31 were down regulated by
prednisolone while CCR6, IL12B, TNFSF8, TNFRSF7 and
TNFRSF17 showed an up regulation.
Also several components of the Wnt signalling pathway
were significantly regulated at protein level (Table 2,
indicated with a blue background). DKK4 an inhibitor of
the Wnt signalling pathways was up-regulated. Furthermore
downstream regulators of the Wnt signalling pathway, LRP6
and WISP1 are down regulated. Additionally, initiation of
insulin signalling is represented by the down regulation of
IGFBP5, IGFBP3 and Resistin.
These results indicate that the regulation of the Akt/insulin
signalling, cytokine signalling and Wnt signalling pathways
by prednisolone is not only found on the transcriptome level,
but is also translated into altered proteins levels in these
pathways.
Regulation of the Wnt signalling pathway by
prednisolone
Individual Wnt signalling components were found to be
significantly regulated by prednisolone at both gene and
protein levels. Therefore, we next investigated whether the
entire Wnt signalling pathway was affected by prednisolone.
The KEGG database was used to select genes upstream in the
canonical Wnt signalling pathway that are more exclusively
linked to the Wnt signalling in comparison with down-stream
genes like Smad3, Lef, Tak1 and Ppar, which are also linked
to TGF-b signalling, MAPK signalling and Cell cycle
(Supplementary Table 3). We used the expression profiles
of these 51 Wnt signalling genes to test whether there is a
difference in expression for the entire Wnt signalling pathway
between prednisolone and DMSO treated samples. In this
method, genes that do not meet the FC 42-fold and Pval
50.05 cut offs but may have nevertheless a changed
expression level were taken into consideration. A significant
difference in expression for the entire Wnt signalling pathway
was observed after 6 h (p value¼ 0.031). In Figure 5, the
Figure 2. Regulated probes by prednisolone at 6 h versus at respectively 48 h (A) and 24 h (B). Probes represented by red dots are regulated
at both time points. Probes represented by blue dots are only regulated by prednisolone at 6 h. Probes represented by green dots are only regulated
by prednisolone at 48 h. In B the regulation of the probes by prednisolone after 6 h versus 24 h is shown. The scale on both axes is log2 fold change.
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genes that had the most influence on this difference are
shown. In this figure, the gene expression ratios (open dots)
and protein ratios (black dots) as a result of prednisolone
treatment are also shown. Genes that had an influence on the
difference between DMSO and prednisolone treated samples
and that showed a higher expression in DMSO treated
samples (red bars) were down-regulated because of prednis-
olone treatment (open dots). The same effect on the Wnt
signalling pathway was also seen after 48 h (p value¼ 0.064)
of treatment (Supplementary Figure 3). This analysis indi-
cates that in 3T3-L1 adipocytes, the entire Wnt signalling
pathway is down-regulated by prednisolone.
Discussion and conclusions
The prolonged use of glucocorticoids is hampered by
metabolic side-effects such as insulin resistance, which
eventually leads to diabetes and obesity. Adipose tissue is
thought to play an important role in GC-induced development
of metabolic side effects. The mechanisms behind these side-
effects are not completely understood. Key findings of our
study indicate that prednisolone reduces insulin stimulated
glucose uptake in 3T3-L1 cells, which is reflected by changes
in expression of genes and proteins from the Akt/insulin,
cytokine and Wnt signalling pathways. To our knowledge, this
is the first work that uses a combination of gene expression
and antibody arrays to study effects of prednisolone in
adipocyte cells.
The set of 25 genes that showed regulation by prednisolone
at all time points includes known target genes of the
glucocorticoid receptor, such as Ddit4, Dusp1 and Cebpd
(Toonen et al., 2011; Yang et al., 2005), and genes such as
Fam107a and PDK4, that were also found to be regulated by
prednisolone in in vivo studies of mouse and human (Bastard
et al., 2006; Frijters et al., 2010; Toonen et al., 2011). This
indicates that prednisolone acts via its target genes and
initiates a GC specific response in these 3T3-L1 cells.
Multiple cytokine molecules were regulated by prednisol-
one. Increasing evidence suggests that a chronic low-grade
state of inflammation in adipose tissue contributes to the
development of systemic insulin resistance and diabetes
(Bastard et al., 2006; Harford et al., 2011; Heilbronn &
Campbell, 2008). In the absence of IL1, mice are protected
against high fat diet induced insulin resistance which is
accompanied with a reduction in local adipose tissue inflam-
mation (de Roos et al., 2009; McGillicuddy et al., 2011). Our
results showed up-regulation of IL1 signalling by means
of IL1r1 and IL1rap. This suggests a role of IL-1 signalling
in GC induced development of insulin resistance in 3T3-
L1 cells.
Also other studies reported about the up-regulation of
cytokines such as Il6, Cxcl5, Ccl2 and Cxcl10 in insulin
resistance and obesity (Figure 6) (Bastard et al., 2006; Chavey
et al., 2009; Lagathu et al., 2003; Murdolo et al., 2008;
Rotter et al., 2003; Tateya et al., 2010). In contrast to
Figure 3. Heat map representation of biological pathways identified using CoPub analysis of regulated genes. The colours shading indicates the
significance of the over-represented pathways (based on pval_transformed), from the lowest value shown in red, to the highest value shown in white.
Columns represent the time points at which the pathways have been found after incubation with prednisolone: 1 h (T1); 6 h (T6); 24 h (T24); 48 h (T48).
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Figure 4. Prednisolone induced genes after 1 h (T1), 6 h (T6), 24 h (T24), 48 h (T48). Prednisolone-induced up-regulated genes are shown in red,
prednisolone induced down-regulated genes are shown in green. For clarity genes have been assigned to major pathways. However, one should keep in
mind that genes can belong to multiple pathways depending on the definition of a pathway.
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these studies, we observed a down regulation of expression
of these genes by prednisolone. Based on these results it is
difficult to deduce whether prednisolone-induced regulation
of cytokines in adipocytes contribute to the development of
insulin resistance or are the result of the immune suppressing
properties of prednisolone or a combination of both.
Furthermore our results indicated that the reduction in
insulin stimulated glucose uptake by prednisolone acts partly
via the down regulation of insulin signalling. This regulation
might be mediated by Pten, a known suppressor of insulin
signalling that acts via the PI3K/Akt signalling pathway
(Tang et al., 2005). Additional studies confirm this observa-
tion and suggest an important role of Pten in the development
of insulin resistance and diabetes (Ikubo et al., 2009; Lazar &
Saltiel, 2006; Nakashima et al., 2000).
Again an apparent contrasting effect of prednisolone is the
down regulation of proteins like Igfb3 and resistin that reduce
glucose uptake in adipose tissue (Chan et al., 2005; Kim
et al., 2007).
Inhibition of TGF-b/Smad3 signalling results in dimin-
ished adiposity, improved glucose tolerance and insulin
sensitivity and in the protection from insulin resistance,
diabetes and obesity (Tan et al., 2011; Tsurutani et al., 2011;
Yadav et al., 2011). The observed down regulation of Smad3
suggests that disturbance of glucose uptake and adiposity by
prednisolone in 3T3-L1 cells acts via additional mechanisms.
Activation of the Wnt signalling pathway has been linked
to inhibition of adipogenesis (Bennett et al., 2002;
Christodoulides et al., 2006; Longo et al., 2002; Ouchi
et al., 2010).
Recent studies toward the characterization of the adipocyte
secretome have shown that multiple regulators of the activity
the Wnt signalling are secreted by adipocytes, such as WISP2
and SFRP5 (Lehr et al., 2012; Ouchi et al., 2010).
Interestingly, expression and circulating levels of these factors
are altered in insulin resistance and obesity (Dahlman et al.,
2012; Hu et al., 2012; Mori et al., 2012; Ouchi et al., 2010),
underlying the suggestion that a dysregulated secretion of
Wnt regulators could lead to metabolic disturbances and
eventually into the development of obesity and diabetes
(Ouchi et al., 2010; Jin, 2008; Liu & Habener, 2010; Oh &
Olefsky, 2010; Schinner, 2009). Yet, in the context of our
study, it remains to be investigated to what extent the factors
affected by prednisolone interfere with insulin action in
adipocytes.
Prednisolone induced Pten, Smad3 and Lef1 which are able
to mediate cross-talk between the signalling pathways (Guo &
Wang, 2009). Via the alteration of the Pten function, TGF-b
is able to influence the Akt activity, and via Smad3 the Akt
pathway is able to restrict the TGF-b pathway. Also Smad
activity is involved in the cross-talk between Wnt signalling
and TGF-b signalling, as part of the Smad/b-catenin/Lef
protein complex in the nucleus. These genes could play a
central role in the development of prednisolone induced
metabolic effects because of their ability to connect multiple
pathways (Figure 6). The sometimes opposing effects of
prednisolone on individual pathway members of Smad3 and
Akt in comparison with earlier work, requires additional
in vivo studies in which the systemic effect of prednisolone on
these pathways could be determined.
Figure 5. Wnt signalling genes that have an influence on the difference between prednisolone and DMSO, after 6 h of incubation. Genes that are up-
regulated in DMSO treated samples are shown in red and genes that are up-regulated in prednisolone treated samples are shown in green. Ratios of
prednisolone-induced genes are indicated with open dots. Prednisolone-induced ratios of the proteins are indicated with black dots. Ratios are indicated
in log2 fold change.
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To our knowledge, for the first time it is shown that
prednisolone affects the expression and secretion of Wnt
regulators in adipocytes. The fact that Wnt signalling also
participates in the development of metabolic disturbances in
other tissues (Abiola et al., 2009; Anagnostou & Shepherd,
2008) may direct future work towards a dedicated study of the
Wnt signalling pathway in GC-induced metabolic effects. In
an in vivo setting the Wnt signalling mediated GC effects in
multiple glucose responsive tissues such as muscle tissue,
liver tissue and adipose tissue could be determined. Hence
new GC compounds with an improved efficacy/side effects
ratio should have a reduced effect on components in the Wnt
signalling pathway.
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